Incyte | INCY - Interest Expense On Debt


Incyte reported $605K in Interest Expense on Debt for its fiscal quarter ending in September of 2026.





Interest Expense On Debt Change Date
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Agenus USD 14.67M 1.35M Mar/2026
Agios Pharmaceuticals USD 1.11B 76.57M Jun/2026
Alnylam Pharmaceuticals USD -84.37M 166.42M Sep/2026
Amgen USD 95.64B 94.98B Jun/2026
BioCryst Pharmaceuticals USD 21.71M 7.58M Jun/2026
Biogen USD 72.6M 12.6M Jun/2025
BioMarin Pharmaceutical USD 63.29M 48.34M Jun/2026
Bristol-Myers Squibb USD 403M 4M Sep/2026
Eli Lilly USD 316M 201.3M Sep/2026
Exelixis USD 23.4M 3.9M Sep/2023
Gilead Sciences USD 269M 22M Sep/2026
Incyte USD 605K 23K Sep/2026
Ionis Pharmaceuticals USD 18M 1000K Jun/2026
MacroGenics USD 4.89M 1.55M Mar/2026
Merck USD 525M 46M Jun/2026
Moderna USD 10.96B 527M Jun/2026
Nektar Therapeutics USD 7.94M 1.83M Mar/2026
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Novartis USD 462M 119M Jun/2026
Novartis USD 281M 8M Sep/2025
Pfizer USD 667M 4M Jun/2026
PTC Therapeutics USD 3.21B 42.76M Sep/2026
Puma Biotechnology USD 3.37M 11K Jun/2024
Regeneron Pharmaceuticals USD 11M 1.9M Jun/2026
Sarepta Therapeutics USD 21.51M 205K Jun/2026
Ultragenyx Pharmaceutical USD 22M 1000K Jun/2026
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025